Normal view MARC view ISBD view

PASSAGE OF A CAST OF THE BLADDER PER URETHRAM. [electronic resource]

By:

Barlet, J M

Producer: 20110329Description: 122-3 p. digitalISSN:

0007-1447

Online resources:

Available from publisher's website

In: British medical journal vol. 1

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.

Back to results

141 Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
by Legros, Laurence
142 Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
by Heiblig, Maël
143 Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
by Nicolini, Franck E
144 The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
by Deau, Bénédicte
145 Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
by Cortes, Jorge E
146 Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.
by Nicolini, Franck E
147 Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
by Rea, Delphine
148 Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
by Mahon, François-Xavier
149 Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
by Rousselot, Philippe
150 Reply to J. Richter et al.
by Rousselot, Philippe
151 Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.
by Nicolini, Franck E
152 Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
by Kizilors, Aytug
153 Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
by Kantarjian, Hagop M
154 United States Department of Agriculture-Agricultural Research Service research on natural products for pest management.
by Duke, Stephen O
155 Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
by Deininger, Michael W
156 Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
by Mitchell, Rebecca
157 The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.
by Nicolini, Franck E
158 Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
by Lipton, Jeffrey H
159 Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
by Cortes, Jorge E
160 BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
by Zabriskie, Matthew S